Bristol Myers Squibb's (BMY) Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival and overall survival in an interim analysis of a Phase 3 trial
Importance
Level 1
#BRISTOL-MYERS SQUIBB CO#BMY.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#US EQUITIES